{
    "hands_on_practices": [
        {
            "introduction": "One of the most critical steps in translational medicine is determining a safe starting dose for first-in-human clinical trials. This practice demonstrates the standard industry method, which involves converting a No-Observed-Adverse-Effect Level (NOAEL) from an animal toxicology study into a Human Equivalent Dose (HED) using body surface area scaling. By then applying a composite uncertainty factor, you will learn how to derive the Maximum Recommended Starting Dose (MRSD), a cornerstone of clinical trial safety .",
            "id": "5062042",
            "problem": "A small-molecule therapeutic intended for oral administration has completed a repeat-dose toxicology study in Sprague–Dawley rats, with a No Observed Adverse Effect Level (NOAEL) of $100$ mg/kg/day established over 28 days of daily gavage. For first-in-human planning in translational medicine, you must derive a Maximum Recommended Starting Dose (MRSD) for a single-dose clinical trial using body surface area scaling and an uncertainty framework.\n\nAssume the following scientifically supported bases:\n- Body surface area is proportional to body weight raised to the two-thirds power, that is, $BSA \\propto W^{2/3}$, with the same proportionality constant across species.\n- The adult human reference body weight is 60 kg.\n- The average body weight of the rats used to establish the NOAEL was 0.25 kg.\n- A standard composite uncertainty factor of 10 should be applied to account for inter-species differences (after allometric scaling) and intra-human variability.\n\nStarting from the proportionality of body surface area to body weight raised to the two-thirds power, derive the MRSD for the first-in-human single-dose study. Convert the animal NOAEL expressed in mg/kg/day to a human equivalent dose (HED) in mg/kg/day using body surface area scaling, then apply the composite uncertainty factor to obtain the human MRSD in mg/kg/day, and finally convert to a total daily dose in mg/day for a 60 kg adult.\n\nRound your final answer to three significant figures. Express the final MRSD as milligrams per day (mg/day).",
            "solution": "The problem requires the derivation of a Maximum Recommended Starting Dose (MRSD) for a first-in-human clinical trial based on preclinical toxicology data from rats. The process involves three main steps:\n1.  Conversion of the animal No Observed Adverse Effect Level (NOAEL) to a Human Equivalent Dose (HED) using body surface area (BSA) scaling.\n2.  Application of a composite uncertainty factor (UF) to the HED to determine the MRSD in units of mass per body weight per day.\n3.  Calculation of the total daily dose for a reference human adult.\n\nFirst, we establish the relationship for converting a dose from an animal species to a human equivalent dose based on BSA scaling. The problem states that BSA is proportional to body weight ($W$) raised to the power of two-thirds:\n$$BSA \\propto W^{2/3}$$\nLet $k$ be the constant of proportionality, which is assumed to be the same across species. Thus, $BSA = k W^{2/3}$.\n\nThe fundamental principle of BSA-based dose scaling is that the total administered dose per unit of BSA is equivalent across species to achieve a similar systemic exposure.\n$$ \\frac{\\text{Total Dose}_{human}}{BSA_{human}} = \\frac{\\text{Total Dose}_{rat}}{BSA_{rat}} $$\nThe total dose is the dose per unit body weight (e.g., in mg/kg) multiplied by the body weight ($W$). Let $D_{human}$ represent the HED in mg/kg and $D_{rat}$ represent the animal dose (the NOAEL) in mg/kg.\n$$ \\frac{D_{human} \\cdot W_{human}}{BSA_{human}} = \\frac{D_{rat} \\cdot W_{rat}}{BSA_{rat}} $$\nSubstituting the expression for BSA:\n$$ \\frac{D_{human} \\cdot W_{human}}{k W_{human}^{2/3}} = \\frac{D_{rat} \\cdot W_{rat}}{k W_{rat}^{2/3}} $$\nSimplifying the equation by canceling $k$ and combining the terms involving $W$:\n$$ D_{human} \\cdot W_{human}^{1/3} = D_{rat} \\cdot W_{rat}^{1/3} $$\nSolving for the HED ($D_{human}$):\n$$ HED = D_{human} = D_{rat} \\cdot \\left(\\frac{W_{rat}}{W_{human}}\\right)^{1/3} $$\nThe given values are:\n- Rat NOAEL, $D_{rat} = 100$ mg/kg/day.\n- Average rat body weight, $W_{rat} = 0.25$ kg.\n- Human reference body weight, $W_{human} = 60$ kg.\n\nSubstituting these values into the HED equation:\n$$ HED = 100 \\, \\text{mg/kg/day} \\cdot \\left(\\frac{0.25 \\, \\text{kg}}{60 \\, \\text{kg}}\\right)^{1/3} $$\n$$ HED = 100 \\left(\\frac{1}{240}\\right)^{1/3} \\, \\text{mg/kg/day} $$\n\nNext, we calculate the MRSD by applying the specified uncertainty factor. The standard composite uncertainty factor ($UF_{composite}$) is 10.\n$$ UF_{composite} = 10 $$\nThe MRSD, expressed in mg/kg/day, is obtained by dividing the HED by the composite uncertainty factor. This division ensures the dose is made safer to account for the uncertainties.\n$$ MRSD_{mg/kg/day} = \\frac{HED}{UF_{composite}} = \\frac{100 \\left(\\frac{1}{240}\\right)^{1/3}}{10} $$\n$$ MRSD_{mg/kg/day} = 10 \\left(\\frac{1}{240}\\right)^{1/3} \\, \\text{mg/kg/day} $$\n\nFinally, we convert this dose from mg/kg/day to a total daily dose in mg/day for the reference $60$ kg human.\n$$ MRSD_{mg/day} = MRSD_{mg/kg/day} \\times W_{human} $$\n$$ MRSD_{mg/day} = \\left[ 10 \\left(\\frac{1}{240}\\right)^{1/3} \\right] \\times 60 $$\n$$ MRSD_{mg/day} = 600 \\left(\\frac{1}{240}\\right)^{1/3} \\, \\text{mg/day} $$\n\nNow, we compute the numerical value.\n$$ \\frac{1}{240} \\approx 0.0041666... $$\n$$ \\left(\\frac{1}{240}\\right)^{1/3} \\approx (0.0041666...)^{1/3} \\approx 0.160938 $$\n$$ MRSD_{mg/day} \\approx 600 \\times 0.160938 $$\n$$ MRSD_{mg/day} \\approx 96.5628 \\, \\text{mg/day} $$\nThe problem requires the final answer to be rounded to three significant figures. The fourth significant figure is $6$, so we round up the third digit.\n$$ MRSD_{mg/day} \\approx 96.6 \\, \\text{mg/day} $$",
            "answer": "$$\\boxed{96.6}$$"
        },
        {
            "introduction": "A true assessment of a drug's safety margin relies on comparing the pharmacologically active drug exposure, not just the total amount in the blood. This exercise is built on the 'free drug hypothesis,' which posits that only unbound drug can exert an effect, making it the relevant metric for interspecies comparisons . You will calculate safety margins based on unbound drug concentrations, a critical skill for accurately interpreting toxicology data when plasma protein binding differs between species.",
            "id": "5062025",
            "problem": "A small-molecule candidate intended for chronic oral therapy underwent a Good Laboratory Practice (GLP) 28-day repeat-dose toxicology study in rats. At the no-observed-adverse-effect level (NOAEL) dose on day 28, the following systemic plasma exposures were measured: total maximal plasma concentration $C_{\\max}$ was $80$ mg/L and total area under the plasma concentration–time curve over $24$ hours, $AUC_{0\\text{–}24}$, was $1200$ mg·h/L. In a Phase $2$ clinical study at the intended therapeutic regimen and steady state, total human plasma exposures were $C_{\\max} = 2.5$ mg/L and $AUC_{0\\text{–}24} = 45$ mg·h/L. In vitro plasma protein binding experiments using equilibrium dialysis showed concentration-independent unbound fractions over the relevant ranges: in rat plasma $f_{u,\\text{rat}} = 0.22$ and in human plasma $f_{u,\\text{human}} = 0.06$.\n\nUsing only fundamental definitions and well-tested principles of pharmacology and pharmacokinetics, first explain why unbound $C_{\\max}$ and unbound $AUC$ are the appropriate exposure metrics for defining interspecies safety margins relative to human therapeutic exposures. Then, using the provided protein binding data, compute the unbound safety margins for $C_{\\max}$ and $AUC$ as the ratios of rat NOAEL unbound exposure to human therapeutic unbound exposure. Finally, define the overall safety margin as the lesser of these two unbound safety margins and compute its value.\n\nAssume linear pharmacokinetics and time-invariant, nonsaturable binding over the exposure ranges so that the unbound fraction remains constant. Express the final overall safety margin as a pure number (dimensionless) and round your answer to three significant figures.",
            "solution": "The first part of the task is to explain the rationale for using unbound drug concentrations to determine interspecies safety margins. This rationale is based on the **free drug hypothesis**, a cornerstone principle in pharmacology and pharmacokinetics. According to this hypothesis, only the fraction of the drug that is not bound to plasma proteins (the 'unbound' or 'free' drug) is able to diffuse or be transported across cell membranes to reach its site of action in tissues, where it can elicit a pharmacological or toxicological effect.\n\nIn the systemic circulation, a drug ($D$) exists in a reversible equilibrium with plasma proteins ($P$), primarily albumin and $\\alpha_1$-acid glycoprotein, forming a drug-protein complex ($DP$):\n$$ D + P \\rightleftharpoons DP $$\nThe total concentration of the drug in plasma, $C_{\\text{total}}$, is the sum of the unbound concentration, $C_u$, and the bound concentration, $C_b$.\n$$ C_{\\text{total}} = C_u + C_b $$\nThe unbound fraction, $f_u$, is defined as the ratio of the unbound concentration to the total concentration:\n$$ f_u = \\frac{C_u}{C_{\\text{total}}} $$\nThe drug-protein complex ($DP$) is generally too large to cross biological membranes. Therefore, the concentration of the drug at the pharmacological target site is considered to be in equilibrium with, and thus proportional to, the unbound plasma concentration, $C_u$, rather than the total plasma concentration, $C_{\\text{total}}$. Consequently, the intensity of both therapeutic and adverse effects is better correlated with $C_u$.\n\nPlasma protein binding can vary significantly between species due to differences in protein structures and concentrations. If total plasma concentrations were used for interspecies comparison, large differences in binding could confound the safety assessment. For instance, a higher total concentration in a toxicology species might not necessarily translate to a higher safety risk if the protein binding in that species is much greater (i.e., a lower $f_u$) than in humans, resulting in a comparable or even lower unbound concentration. By using unbound concentrations ($C_u = f_u \\times C_{\\text{total}}$), we normalize for these interspecies differences in plasma protein binding, allowing for a more direct and scientifically valid comparison of the pharmacologically active moiety. Therefore, unbound maximal concentration ($C_{\\max,u}$) and unbound area under the curve ($AUC_u$) are the correct metrics for establishing safety margins.\n\nThe second part of the task is to compute the safety margins. We are given the following data:\n- Rat NOAEL exposures (total): $C_{\\max, \\text{rat}} = 80$ mg/L, $AUC_{0\\text{–}24, \\text{rat}} = 1200$ mg·h/L\n- Human therapeutic exposures (total): $C_{\\max, \\text{human}} = 2.5$ mg/L, $AUC_{0\\text{–}24, \\text{human}} = 45$ mg·h/L\n- Unbound fractions: $f_{u,\\text{rat}} = 0.22$, $f_{u,\\text{human}} = 0.06$\n\nFirst, we calculate the unbound exposures in both species. The assumption of constant unbound fraction allows us to write:\n$$ C_{\\max,u} = f_u \\times C_{\\max,\\text{total}} $$\n$$ AUC_{u} = f_u \\times AUC_{\\text{total}} $$\n\nFor the rat at the NOAEL:\n$ C_{\\max, u, \\text{rat}} = f_{u,\\text{rat}} \\times C_{\\max, \\text{rat}} = 0.22 \\times 80 \\text{ mg/L} = 17.6 \\text{ mg/L} $\n$ AUC_{0\\text{–}24, u, \\text{rat}} = f_{u,\\text{rat}} \\times AUC_{0\\text{–}24, \\text{rat}} = 0.22 \\times 1200 \\text{ mg·h/L} = 264 \\text{ mg·h/L} $\n\nFor the human at the therapeutic dose:\n$ C_{\\max, u, \\text{human}} = f_{u,\\text{human}} \\times C_{\\max, \\text{human}} = 0.06 \\times 2.5 \\text{ mg/L} = 0.15 \\text{ mg/L} $\n$ AUC_{0\\text{–}24, u, \\text{human}} = f_{u,\\text{human}} \\times AUC_{0\\text{–}24, \\text{human}} = 0.06 \\times 45 \\text{ mg·h/L} = 2.7 \\text{ mg·h/L} $\n\nNext, we compute the safety margin (SM) for both $C_{\\max}$ and $AUC$ as the ratio of the unbound exposure at the NOAEL in the toxicology species (rat) to the unbound exposure at the therapeutic level in humans.\n\nSafety margin based on $C_{\\max}$:\n$$ SM_{C_{\\max}} = \\frac{C_{\\max, u, \\text{rat}}}{C_{\\max, u, \\text{human}}} = \\frac{17.6}{0.15} \\approx 117.333... $$\n\nSafety margin based on $AUC$:\n$$ SM_{AUC} = \\frac{AUC_{0\\text{–}24, u, \\text{rat}}}{AUC_{0\\text{–}24, u, \\text{human}}} = \\frac{264}{2.7} \\approx 97.777... $$\n\nFinally, the problem defines the overall safety margin as the lesser of these two calculated values. This is a standard conservative practice in toxicology, as the toxicity could be driven by either peak exposure ($C_{\\max}$) or total exposure over time ($AUC$).\n$$ \\text{Overall Safety Margin} = \\min(SM_{C_{\\max}}, SM_{AUC}) $$\n$$ \\text{Overall Safety Margin} = \\min(117.333..., 97.777...) = 97.777... $$\n\nRounding this result to three significant figures, as required, gives $97.8$.",
            "answer": "$$\\boxed{97.8}$$"
        },
        {
            "introduction": "When a drug is administered repeatedly, its concentration in the body builds up until a 'steady state' is reached, where the rate of administration equals the rate of elimination. Understanding this accumulation is crucial for designing and interpreting repeat-dose toxicology studies and predicting human exposure profiles . This practice will guide you through deriving and calculating the accumulation ratio and the time required to reach steady state, two key pharmacokinetic parameters.",
            "id": "5062065",
            "problem": "A once-daily repeat-dose toxicology study is being designed to evaluate systemic exposure escalation from single-dose to steady-state conditions under linear pharmacokinetics in a nonclinical species. Assume first-order elimination, dose superposition, and that the area under the concentration-time curve (AUC) scales linearly with dose and concentration. Let the drug’s terminal half-life be $t_{1/2}=12\\,\\text{h}$ and the dosing interval be $\\tau=24\\,\\text{h}$.\n\nStarting only from the definitions of first-order elimination and superposition, and from geometric series summation, perform the following:\n\n1) Derive the expression for the accumulation ratio $R_{\\mathrm{ac}}$ that relates any proportional steady-state exposure metric over one dosing interval (for example, peak concentration, trough concentration, or area under the concentration-time curve (AUC)) to the corresponding single-dose metric. Evaluate $R_{\\mathrm{ac}}$ numerically for the given $t_{1/2}$ and $\\tau$.\n\n2) Define “steady state” operationally as the time $t_{f}$ at which the fraction of the asymptotic steady-state level achieved at dosing instants is $f=0.95$. Derive an expression for $t_{f}$ in terms of $k$ and $f$, where $k$ is the first-order elimination rate constant, and then compute $t_{f}$ for $f=0.95$ given $t_{1/2}=12\\,\\text{h}$. Express $t_{f}$ in days.\n\nReport your final answers as a two-entry row vector $\\bigl[R_{\\mathrm{ac}},\\,t_{f,\\text{days}}\\bigr]$. Round both entries to four significant figures. Express the time in days; $R_{\\mathrm{ac}}$ is dimensionless.",
            "solution": "The problem is evaluated to be scientifically sound, well-posed, and self-contained. The provided information is sufficient and consistent for deriving the requested quantities. The problem will be solved in two parts as requested.\n\nThe fundamental assumptions are first-order elimination kinetics and dose superposition. First-order elimination implies that the rate of drug elimination is proportional to the drug concentration $C$, described by the differential equation $\\frac{dC}{dt} = -kC$, where $k$ is the first-order elimination rate constant. The solution to this equation is $C(t) = C_{\\text{initial}} e^{-kt}$. The rate constant $k$ is related to the drug's half-life $t_{1/2}$ by the formula $k = \\frac{\\ln(2)}{t_{1/2}}$.\n\nGiven $t_{1/2} = 12\\,\\text{h}$ and the dosing interval $\\tau = 24\\,\\text{h}$, the term $k\\tau$ can be calculated as:\n$$\nk\\tau = \\frac{\\ln(2)}{t_{1/2}} \\tau = \\frac{\\ln(2)}{12\\,\\text{h}} \\times 24\\,\\text{h} = 2\\ln(2) = \\ln(2^2) = \\ln(4)\n$$\nThis value will be used in the subsequent derivations.\n\n**1) Derivation and Calculation of the Accumulation Ratio $R_{\\mathrm{ac}}$**\n\nThe accumulation ratio, $R_{\\mathrm{ac}}$, is the ratio of an exposure metric at steady state to the corresponding metric after a single dose. We will derive this using the area under the concentration-time curve (AUC) over one dosing interval, $\\tau$.\n\nLet us assume, without loss of generality, that each dose is administered as an intravenous bolus, resulting in an initial concentration increase of $C_0$. After a single dose, the concentration at time $t$ is $C_1(t) = C_0 e^{-kt}$. The AUC over the first dosing interval, from $t=0$ to $t=\\tau$, is:\n$$\n\\mathrm{AUC}_{0-\\tau, \\text{single dose}} = \\int_0^\\tau C_1(t) dt = \\int_0^\\tau C_0 e^{-kt} dt = C_0 \\left[ -\\frac{1}{k} e^{-kt} \\right]_0^\\tau = \\frac{C_0}{k} (1 - e^{-k\\tau})\n$$\nAt steady state ($ss$), the concentration profile is periodic. The principle of superposition states that the concentration at steady state is the sum of concentrations remaining from an infinite series of previous doses. The concentration just before a dose at steady state (trough concentration, $C_{\\mathrm{min},ss}$) is the sum of the residual concentrations from all prior doses:\n$$\nC_{\\mathrm{min},ss} = \\sum_{n=1}^{\\infty} C_0 e^{-nk\\tau}\n$$\nThis is a geometric series with first term $a = C_0 e^{-k\\tau}$ and common ratio $r = e^{-k\\tau}$. Since $k>0$ and $\\tau>0$, $|r|<1$, and the series converges to $S=\\frac{a}{1-r}$:\n$$\nC_{\\mathrm{min},ss} = \\frac{C_0 e^{-k\\tau}}{1 - e^{-k\\tau}}\n$$\nThe peak concentration immediately after a dose at steady state, $C_{\\mathrm{max},ss}$, is the trough concentration plus the new dose:\n$$\nC_{\\mathrm{max},ss} = C_{\\mathrm{min},ss} + C_0 = \\frac{C_0 e^{-k\\tau}}{1 - e^{-k\\tau}} + C_0 = \\frac{C_0 e^{-k\\tau} + C_0(1 - e^{-k\\tau})}{1 - e^{-k\\tau}} = \\frac{C_0}{1 - e^{-k\\tau}}\n$$\nThe concentration over one dosing interval at steady state, for $t$ from $0$ to $\\tau$ within that interval, is $C_{ss}(t) = C_{\\mathrm{max},ss} e^{-kt}$. The AUC over one dosing interval at steady state is:\n$$\n\\mathrm{AUC}_{\\tau,ss} = \\int_0^{\\tau} C_{ss}(t) dt = \\int_0^{\\tau} C_{\\mathrm{max},ss} e^{-kt} dt = \\frac{C_{\\mathrm{max},ss}}{k} (1 - e^{-k\\tau})\n$$\nSubstituting the expression for $C_{\\mathrm{max},ss}$:\n$$\n\\mathrm{AUC}_{\\tau,ss} = \\frac{1}{k} \\left( \\frac{C_0}{1 - e^{-k\\tau}} \\right) (1 - e^{-k\\tau}) = \\frac{C_0}{k}\n$$\nThe accumulation ratio $R_{\\mathrm{ac}}$ is defined as the ratio of the steady-state AUC over one interval to the single-dose AUC over one interval:\n$$\nR_{\\mathrm{ac}} = \\frac{\\mathrm{AUC}_{\\tau,ss}}{\\mathrm{AUC}_{0-\\tau, \\text{single dose}}} = \\frac{C_0/k}{\\frac{C_0}{k}(1 - e^{-k\\tau})} = \\frac{1}{1 - e^{-k\\tau}}\n$$\nThis expression is general for any exposure metric that scales linearly with concentration.\n\nNow, we evaluate $R_{\\mathrm{ac}}$ numerically using $k\\tau = \\ln(4)$:\n$$\nR_{\\mathrm{ac}} = \\frac{1}{1 - e^{-\\ln(4)}} = \\frac{1}{1 - \\frac{1}{4}} = \\frac{1}{\\frac{3}{4}} = \\frac{4}{3}\n$$\nNumerically, $R_{\\mathrm{ac}} = 1.3333...$. Rounding to four significant figures gives $R_{\\mathrm{ac}} = 1.333$.\n\n**2) Derivation and Calculation of Time to Reach $95\\%$ of Steady State, $t_f$**\n\nSteady state is approached exponentially. We analyze the accumulation of drug concentration at a specific point in the dosing interval, for instance, the peak concentration immediately after dosing. The peak concentration after the $n$-th dose, $C_{\\mathrm{max},n}$, is the sum of concentrations from the current dose and all previous doses:\n$$\nC_{\\mathrm{max},n} = \\sum_{i=0}^{n-1} C_0 e^{-ik\\tau} = C_0 \\sum_{i=0}^{n-1} (e^{-k\\tau})^i\n$$\nThis is a finite geometric series with $n$ terms, first term $a=C_0$, and ratio $r=e^{-k\\tau}$. The sum is $S_n = a \\frac{1-r^n}{1-r}$.\n$$\nC_{\\mathrm{max},n} = C_0 \\frac{1 - e^{-nk\\tau}}{1 - e^{-k\\tau}}\n$$\nWe know that $C_{\\mathrm{max},ss} = \\frac{C_0}{1 - e^{-k\\tau}}$. Therefore, we can write $C_{\\mathrm{max},n}$ in terms of $C_{\\mathrm{max},ss}$:\n$$\nC_{\\mathrm{max},n} = C_{\\mathrm{max},ss} (1 - e^{-nk\\tau})\n$$\nThe fraction of the steady-state level achieved after the $n$-th dose is $\\frac{C_{\\mathrm{max},n}}{C_{\\mathrm{max},ss}} = 1 - e^{-nk\\tau}$.\nThe problem defines $t_f$ as the time at which this fraction is $f$. The time course of accumulation towards steady state is governed by the term $1 - e^{-kt}$. We can therefore set $t_f$ as the time in this continuous model where the fraction $f$ of the final value is reached.\n$$\nf = 1 - e^{-kt_f}\n$$\nThis approach is valid because the time constant for accumulation is determined solely by the elimination rate constant $k$, not by the dosing interval $\\tau$. Solving for $t_f$:\n$$\ne^{-kt_f} = 1 - f\n$$\n$$\n-kt_f = \\ln(1 - f)\n$$\n$$\nt_f = -\\frac{\\ln(1-f)}{k}\n$$\nWe can substitute $k = \\frac{\\ln(2)}{t_{1/2}}$ to get an expression in terms of the half-life:\n$$\nt_f = - \\frac{\\ln(1-f)}{\\frac{\\ln(2)}{t_{1/2}}} = t_{1/2} \\frac{-\\ln(1-f)}{\\ln(2)}\n$$\nNow, we compute $t_f$ for $f=0.95$ and $t_{1/2}=12\\,\\text{h}$:\n$$\nt_f = 12\\,\\text{h} \\times \\frac{-\\ln(1-0.95)}{\\ln(2)} = 12\\,\\text{h} \\times \\frac{-\\ln(0.05)}{\\ln(2)}\n$$\nUsing the values $\\ln(0.05) \\approx -2.995732$ and $\\ln(2) \\approx 0.693147$:\n$$\nt_f \\approx 12\\,\\text{h} \\times \\frac{2.995732}{0.693147} \\approx 12\\,\\text{h} \\times 4.321928 \\approx 51.8631\\,\\text{h}\n$$\nThe problem requires the answer in days. We convert hours to days by dividing by $24$:\n$$\nt_{f,\\text{days}} = \\frac{51.8631}{24} \\approx 2.160964\\,\\text{days}\n$$\nRounding to four significant figures gives $t_{f,\\text{days}} = 2.161$.\n\nThe final answer is the two-entry row vector $\\begin{pmatrix} R_{\\mathrm{ac}} & t_{f,\\text{days}} \\end{pmatrix}$.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n1.333 & 2.161\n\\end{pmatrix}\n}\n$$"
        }
    ]
}